Open AccessErtapenem Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections
Author(s) -
Joseph S. Solomkin,
Albert E. Yellin,
Ori D. Rotstein,
Nicolas V. Christou,
E. Patchen Dellinger,
José M. Tellado,
Osvaldo Malafaia,
Álvaro F. Fernández,
Kyuran A. Choe,
Alexandra D. Carides,
Vilas Satishchandran,
Hedy Teppler
Publication year - 2003
Publication title -
annals of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.153
H-Index - 309
eISSN - 1528-1140
pISSN - 0003-4932
DOI - 10.1097/01.sla.0000048551.32606.73
Subject(s) - ertapenem , medicine , piperacillin/tazobactam , tazobactam , piperacillin , population , antibacterial agent , surgery , cefotetan , intensive care medicine , antibiotics , meropenem , antibiotic resistance , microbiology and biotechnology , environmental health , imipenem , genetics , bacteria , pseudomonas aeruginosa , biology
To examine the clinical efficacy and safety of ertapenem, a novel beta-lactam agent with wide activity against common pathogens encountered in intraabdominal infection.